Systematic review: Impaired drug absorption related to the co-administration of antisecretory therapy

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 12, 2009, Pages 1219-1229

  Lahner, E ^a   Annibale, B ^a   Delle Fave, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

DRUG ADMINISTRATION; DRUG EFFECT; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE ABSORPTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECRETION; STOMACH ACID; STOMACH MUCOSA;

ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; GASTRIC ACID; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 76249083093     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03993.x     Document Type: Review

References (51)

1. Hou W, Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2006; 22: 593-8. (Pubitemid 44624524)
2. Garnett WR. Considerations for long-term use of proton-pump inhibitors. Am J Health Syst Pharm 1998; 55: 2268-79. (Pubitemid 28510085)
3. Welage LS, Berardi SS. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acidrelated diseases. J Am Pharm Assoc 2000; 40: 52-62.
4. Walt RP, Gomes MD, Wood EC, Logan LH, Pounder RE. Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 1983; 287: 12-4. (Pubitemid 13062821)
5. Prichard PJ, Yeomans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 64-9. (Pubitemid 15177641)
6. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel, Switzerland: S. Karger, 1995: 240-57.
7. Vanderhoff BT, Rundsarah MT. Proton pump inhibitors: an update. Am Fam Physician 2002; 66: 273-80. (Pubitemid 34810080)
8. Kuipers EJ, Meuwissen SGM. The efficacy and safety of long-term omeprazole treatment for gastroesophageal reflux disease. Gastroenterology 2000; 118: 795-801.
9. Arnold R. Safety of proton pump inhibitors - an overview. Aliment Pharmacol Ther 1994; 8: 65-70. (Pubitemid 24203344)
10. Evenepoel P. Alteration in digestion and absorption of nutrients during profound acid suppression. Best Pract Res Clin Gastroenterol 2001; 15: 539-51. (Pubitemid 32590885)
11. Laine L, Ahnen D, Mcclain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-68. (Pubitemid 30352732)
12. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53. (Pubitemid 46021498)
13. Hirtz J. The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol 1985; 19: 775.
14. Golub AL, Frost RW, Betlach CJ, Gonzalez MA. Physiologic considerations in drug absorption from the gastrointestinal tract. J Allergy Clin Immunol 1986; 78: 689-94. (Pubitemid 17170582)
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting Metaanalyses. Lancet 1999; 354: 1896-900.
16. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7: iii-x, 1-173.
17. McColl KE, El-Omar E, Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 2000; 29: 687-703.
18. Feldman M, Cryer B, Lee E. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol 1998; 274: G1011-7.
19. Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 2009; 29: 379-86.
20. Jadad AR, McQuay HJ. Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. J Clin Epidemiol 1996; 49: 235-43. (Pubitemid 26123935)
21. Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad Quality Score for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord 2001; 12: 232-6. (Pubitemid 32217854)
22. Lelawongs P, Barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988; 3: 228-35.
23. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755-7.
24. Piscitelli SC, Goss TF, Wilton J, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sulcralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991; 35: 1765-71.
25. Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agent Chemother 1995; 39: 1671-5.
26. Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993; 7: 317-21. (Pubitemid 23198307)
27. Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006; 26: 341-6. (Pubitemid 43334673)
28. Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 1989; 46: 674-85. (Pubitemid 20031850)
29. Grasela TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 1989; 33: 615-7. (Pubitemid 19119998)
30. Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption. Clin Pharmacol Ther 1992; 52: 252-6.
31. Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol 2005; 45: 845-50. (Pubitemid 40875337)
32. Soons PA, Van den Berg G, Danhof M, et al. Influence of single- and multipledose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992; 42: 319-24.
33. Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, Wurst W. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 1996; 34: 51-5. (Pubitemid 26053099)
34. Oosterhuis B, Jonkman JHG, Andersson T, Zuiderwijk PBM, Jedema JN. Minor effect of mulitple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmac 1991; 32: 569-72.
35. Cohen AF, Kroon R, Schoemaker R, Hoogkamer H, Van Vliet A. Influence of gastric acidity of the bioavailability of digoxin. Ann Int Med 1991; 115: 540-5.
36. Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 1996; 34(Suppl 1): S67-71. (Pubitemid 26182714)
37. Gertz BJ, Sherry DH, Kline WF, et al. Studies on the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58: 288-98.
38. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Eng J Med 1994; 330: 263-72. (Pubitemid 24034139)
39. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharamokinet 1988; 14: 13-34.
40. Bailey EM, Krakovsky DJ, Rybak M. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 1990; 10: 146-53. (Pubitemid 20149608)
41. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63: 1679-95.
42. Russell TL, Berardi RR, Barnett JL, O'Sullivan TL, Wagner JG, Dressman JB. pH-related changes in the absorption of dipyridamole in the elderly. Pharm Res 1994; 11: 136-43. (Pubitemid 24040777)
43. Gault H, Kalra J, Ahmed M, Kepkay D, Longerich L, Barrowman J. Influence of gastric pH on digoxin biotransformation. II. Extractable urinary metabolite. Clin Pharmacol Ther 1981; 29: 181-90. (Pubitemid 11139894)
44. Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphoshonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991; 15: 237-48.
45. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1992; 76: 1399-406. (Pubitemid 23164351)
46. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-base therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
47. Papp-Jambor C, Jaschinkski U, Forst H. Cytochrome P450 enzymes and their role in drug interactions. Anesthesist 2002; 51: 2-15. (Pubitemid 34146200)
48. Laupacis A, Straus S. Systematic Reviews: time to address clinical and policy relevance as well as methodological rigor. Ann Intern Med 2007; 147: 273-4. (Pubitemid 351664584)
49. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory medications. N Engl J Med 1999; 340: 1888-99. (Pubitemid 29272670)
50. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003; 98: 51-8. (Pubitemid 36135169)
51. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317: 452-6. (Pubitemid 28368037)